Harmony Biosciences Holdings Key Executives
This section highlights Harmony Biosciences Holdings's key executives, including their titles and compensation details.
Find Contacts at Harmony Biosciences Holdings
(Showing 0 of )
Harmony Biosciences Holdings Earnings
This section highlights Harmony Biosciences Holdings's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-25 | $0.74 | $0.85 |
| Read Transcript | Q3 | 2024 | 2024-10-29 | $0.67 | $0.79 |
| Read Transcript | Q2 | 2024 | 2024-08-06 | $-0.06 | $0.20 |
| Read Transcript | Q1 | 2024 | 2024-04-30 | $0.60 | $0.67 |
| Read Transcript | Q4 | 2023 | 2024-02-22 | $0.48 | $0.45 |
| Read Transcript | Q3 | 2023 | 2023-11-01 | N/A | N/A |
| Read Transcript | Q2 | 2023 | 2023-08-01 | $0.63 | $0.56 |
| Read Transcript | Q1 | 2023 | 2023-05-02 | $0.44 | $0.48 |
Financial Statements
Access annual & quarterly financial statements for Harmony Biosciences Holdings, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $714.73M | $582.02M | $437.86M | $305.44M | $159.74M |
| Cost of Revenue | $156.81M | $121.24M | $83.48M | $55.52M | $27.74M |
| Gross Profit | $557.92M | $460.79M | $354.37M | $249.92M | $132.00M |
| Gross Profit Ratio | 78.06% | 79.17% | 80.93% | 81.82% | 82.64% |
| Research and Development Expenses | $145.82M | $76.06M | $70.89M | $30.37M | $19.45M |
| General and Administrative Expenses | $110.35M | $95.29M | $84.02M | $63.91M | $39.75M |
| Selling and Marketing Expenses | $110.92M | $97.40M | $79.28M | $68.12M | $55.82M |
| Selling General and Administrative Expenses | $221.27M | $192.69M | $163.30M | $132.03M | $95.57M |
| Other Expenses | $- | $- | $169.00K | $16.00K | $-3.07M |
| Operating Expenses | $367.09M | $268.76M | $234.19M | $162.39M | $115.02M |
| Cost and Expenses | $523.91M | $389.99M | $317.67M | $217.91M | $142.76M |
| Interest Income | $18.54M | $14.73M | $3.13M | $223.00K | $28.22M |
| Interest Expense | $17.50M | $23.76M | $15.67M | $23.97M | $28.22M |
| Depreciation and Amortization | $24.11M | $24.36M | $23.39M | $18.84M | $10.24M |
| EBITDA | $233.41M | $221.51M | $143.57M | $106.37M | $1.51M |
| EBITDA Ratio | 32.66% | 38.06% | 32.79% | 34.82% | 0.95% |
| Operating Income | $190.83M | $192.03M | $120.19M | $68.70M | $3.68M |
| Operating Income Ratio | 26.70% | 32.99% | 27.45% | 22.49% | 2.30% |
| Total Other Income Expenses Net | $978.00K | $-18.63M | $-15.50M | $-50.10M | $-53.93M |
| Income Before Tax | $191.80M | $173.40M | $104.69M | $37.43M | $-36.94M |
| Income Before Tax Ratio | 26.84% | 29.79% | 23.91% | 12.25% | -23.13% |
| Income Tax Expense | $46.31M | $44.54M | $-76.78M | $2.83M | $14.91M |
| Net Income | $145.49M | $128.85M | $181.47M | $34.60M | $-51.86M |
| Net Income Ratio | 20.36% | 22.14% | 41.44% | 11.33% | -32.46% |
| EPS | $2.56 | $2.17 | $3.07 | $0.60 | $-0.91 |
| EPS Diluted | $2.51 | $2.13 | $2.97 | $0.58 | $-0.91 |
| Weighted Average Shares Outstanding | 56.89M | 59.47M | 59.17M | 57.53M | 56.89M |
| Weighted Average Shares Outstanding Diluted | 57.87M | 60.37M | 61.10M | 59.21M | 56.89M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $201.27M | $186.04M | $172.81M | $154.62M | $168.41M | $160.27M | $134.22M | $119.13M | $128.31M | $117.21M | $107.03M | $85.31M | $91.21M | $80.73M | $73.82M | $59.67M | $56.29M | $45.61M | $38.01M | $19.84M |
| Cost of Revenue | $54.41M | $42.78M | $38.10M | $33.45M | $43.15M | $32.30M | $25.01M | $20.78M | $26.89M | $22.96M | $18.92M | $14.72M | $17.82M | $14.60M | $12.69M | $10.41M | $9.92M | $7.89M | $6.46M | $3.47M |
| Gross Profit | $146.86M | $143.26M | $134.71M | $121.17M | $125.26M | $127.97M | $109.21M | $98.35M | $101.42M | $94.25M | $88.11M | $70.60M | $73.40M | $66.13M | $61.13M | $49.27M | $46.37M | $37.72M | $31.55M | $16.37M |
| Gross Profit Ratio | 72.97% | 77.01% | 77.95% | 78.37% | 74.38% | 79.85% | 81.37% | 82.56% | 79.05% | 80.41% | 82.32% | 82.75% | 80.47% | 81.91% | 82.81% | 82.56% | 82.38% | 82.70% | 83.01% | 82.49% |
| Research and Development Expenses | $34.67M | $25.39M | $63.58M | $22.19M | $30.31M | $17.50M | $14.97M | $13.29M | $10.09M | $40.55M | $12.67M | $7.58M | $7.45M | $11.74M | $6.50M | $4.68M | $7.62M | $4.23M | $4.17M | $3.43M |
| General and Administrative Expenses | $28.86M | $28.59M | $27.22M | $25.68M | $27.87M | $22.55M | $22.81M | $22.06M | $22.64M | $21.33M | $22.16M | $17.88M | $18.20M | $16.86M | $14.30M | $14.55M | $13.47M | $10.51M | $7.63M | $9.29M |
| Selling and Marketing Expenses | $27.60M | $27.58M | $28.51M | $27.23M | $26.89M | $23.42M | $24.53M | $22.57M | $21.07M | $20.47M | $20.16M | $17.58M | $19.11M | $16.48M | $17.02M | $15.51M | $17.53M | $12.60M | $12.44M | $13.25M |
| Selling General and Administrative Expenses | $56.47M | $56.16M | $49.77M | $46.95M | $54.76M | $45.96M | $47.34M | $44.63M | $43.72M | $41.80M | $42.32M | $35.46M | $37.31M | $33.34M | $31.32M | $30.05M | $30.99M | $23.11M | $20.07M | $22.54M |
| Other Expenses | $- | $- | $37.00K | $-141.00K | $193.00K | $-5.00K | $-31.00K | $2.00K | $73.00K | $56.00K | $42.00K | $-2.00K | $31.00K | $- | $4.00K | $-20.00K | $- | $-1.52M | $-400.00K | $- |
| Operating Expenses | $91.13M | $81.55M | $113.35M | $69.14M | $85.06M | $63.46M | $62.31M | $57.92M | $53.81M | $82.35M | $54.99M | $43.04M | $44.77M | $45.08M | $37.82M | $34.73M | $38.61M | $27.34M | $24.24M | $25.98M |
| Cost and Expenses | $145.54M | $124.33M | $151.46M | $102.58M | $128.22M | $95.76M | $87.31M | $78.70M | $80.69M | $105.31M | $73.91M | $57.76M | $62.58M | $59.68M | $50.51M | $45.14M | $48.53M | $35.23M | $30.70M | $29.45M |
| Interest Income | $4.48M | $4.93M | $4.71M | $4.43M | $4.10M | $4.11M | $3.44M | $3.09M | $1.86M | $941.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $4.21M | $4.35M | $4.40M | $4.54M | $15.43M | $2.91M | $2.78M | $2.65M | $3.58M | $3.99M | $3.93M | $4.17M | $4.19M | $5.43M | $7.23M | $7.13M | $7.97M | $6.95M | $- | $- |
| Depreciation and Amortization | $5.97M | $5.97M | $6.05M | $6.12M | $6.12M | $6.11M | $6.06M | $6.06M | $6.07M | $6.06M | $6.05M | $5.20M | $4.76M | $4.67M | $4.73M | $4.68M | $4.38M | $1.97M | $2.00M | $1.88M |
| EBITDA | $66.33M | $72.49M | $27.41M | $58.16M | $46.32M | $70.61M | $52.97M | $46.49M | $53.68M | $17.96M | $39.17M | $32.76M | $33.39M | $-361.00K | $28.04M | $19.21M | $12.14M | $10.82M | $9.31M | $-7.73M |
| EBITDA Ratio | 32.96% | 38.96% | 15.86% | 37.61% | 27.50% | 44.06% | 39.46% | 39.02% | 41.84% | 15.33% | 36.60% | 38.39% | 36.61% | -0.45% | 37.99% | 32.19% | 21.57% | 23.73% | 24.50% | -38.94% |
| Operating Income | $55.73M | $61.71M | $21.36M | $52.03M | $40.20M | $64.51M | $46.90M | $40.42M | $47.61M | $11.90M | $33.12M | $27.56M | $28.63M | $21.05M | $23.31M | $14.53M | $7.76M | $10.38M | $7.31M | $-9.61M |
| Operating Income Ratio | 27.69% | 33.17% | 12.36% | 33.65% | 23.87% | 40.25% | 34.95% | 33.93% | 37.11% | 10.15% | 30.94% | 32.30% | 31.39% | 26.08% | 31.58% | 24.35% | 13.79% | 22.76% | 19.23% | -48.43% |
| Total Other Income Expenses Net | $428.00K | $460.00K | $338.00K | $-248.00K | $-507.00K | $-12.68M | $-2.81M | $-2.64M | $-3.51M | $-3.93M | $-3.88M | $-4.17M | $-4.16M | $-31.57M | $-7.22M | $-7.15M | $-7.97M | $-8.47M | $-7.34M | $-29.01M |
| Income Before Tax | $56.16M | $62.17M | $21.69M | $51.78M | $39.69M | $51.83M | $44.09M | $37.78M | $44.10M | $7.97M | $29.23M | $23.39M | $24.48M | $-10.52M | $16.09M | $7.39M | $-206.00K | $1.91M | $-27.00K | $-38.62M |
| Income Before Tax Ratio | 27.90% | 33.42% | 12.55% | 33.49% | 23.57% | 32.34% | 32.85% | 31.71% | 34.37% | 6.80% | 27.31% | 27.41% | 26.83% | -13.03% | 21.79% | 12.38% | -0.37% | 4.19% | -0.07% | -194.66% |
| Income Tax Expense | $6.68M | $16.08M | $10.10M | $13.45M | $13.08M | $13.37M | $9.79M | $8.29M | $-4.41M | $-79.98M | $5.70M | $1.90M | $1.76M | $-902.00K | $1.97M | $7.13M | $-4.38M | $5.42M | $6.94M | $29.01M |
| Net Income | $49.48M | $46.09M | $11.59M | $38.33M | $26.61M | $38.46M | $34.30M | $29.48M | $48.51M | $87.94M | $23.53M | $21.48M | $22.71M | $-9.62M | $14.12M | $7.39M | $-206.00K | $1.91M | $-27.00K | $-38.62M |
| Net Income Ratio | 24.58% | 24.78% | 6.71% | 24.79% | 15.80% | 24.00% | 25.56% | 24.75% | 37.81% | 75.03% | 21.99% | 25.18% | 24.90% | -11.92% | 19.12% | 12.38% | -0.37% | 4.19% | -0.07% | -194.66% |
| EPS | $0.87 | $0.81 | $0.20 | $0.68 | $0.46 | $0.64 | $0.57 | $0.49 | $0.82 | $1.48 | $0.40 | $0.36 | $0.39 | $-0.17 | $0.25 | $0.13 | $0.00 | $-0.14 | $0.00 | $-0.70 |
| EPS Diluted | $0.85 | $0.79 | $0.20 | $0.67 | $0.45 | $0.63 | $0.56 | $0.48 | $0.79 | $1.44 | $0.39 | $0.35 | $0.38 | $-0.17 | $0.24 | $0.13 | $0.00 | $-0.14 | $0.00 | $-0.70 |
| Weighted Average Shares Outstanding | 57.10M | 56.87M | 56.80M | 56.77M | 58.32M | 59.86M | 59.97M | 59.73M | 59.48M | 59.23M | 59.06M | 58.91M | 58.55M | 56.59M | 56.94M | 56.89M | 56.89M | 29.31M | 62.98M | 55.28M |
| Weighted Average Shares Outstanding Diluted | 58.22M | 58.10M | 57.54M | 57.60M | 58.85M | 60.68M | 60.74M | 61.22M | 61.62M | 61.21M | 60.92M | 60.59M | 60.31M | 57.72M | 58.59M | 58.81M | 56.89M | 30.21M | 62.98M | 55.28M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $453.00M | $311.66M | $243.78M | $234.31M | $228.63M |
| Short Term Investments | $14.19M | $41.80M | $79.33M | $- | $- |
| Cash and Short Term Investments | $467.19M | $353.46M | $323.12M | $234.31M | $228.63M |
| Net Receivables | $83.03M | $74.14M | $54.74M | $34.84M | $22.18M |
| Inventory | $7.20M | $5.36M | $4.30M | $4.43M | $3.82M |
| Other Current Assets | $21.84M | $18.11M | $18.13M | $10.86M | $8.26M |
| Total Current Assets | $579.25M | $451.07M | $400.29M | $284.44M | $262.89M |
| Property Plant Equipment Net | $1.26M | $371.00K | $573.00K | $820.00K | $938.00K |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $113.26M | $137.11M | $160.95M | $143.92M | $162.34M |
| Goodwill and Intangible Assets | $113.26M | $137.11M | $160.95M | $143.92M | $162.34M |
| Long Term Investments | $108.87M | $72.17M | $22.57M | $750.00K | $750.00K |
| Tax Assets | $190.40M | $144.16M | $85.94M | $-750.00K | $-750.00K |
| Other Non-Current Assets | $6.16M | $6.57M | $3.55M | $4.26M | $902.00K |
| Total Non-Current Assets | $419.95M | $360.38M | $273.58M | $149.00M | $164.18M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $999.20M | $811.45M | $673.87M | $433.44M | $427.07M |
| Account Payables | $13.74M | $17.73M | $3.79M | $1.00M | $2.56M |
| Short Term Debt | $16.25M | $15.00M | $2.00M | $2.00M | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $49.41M | $- |
| Other Current Liabilities | $145.09M | $131.05M | $73.10M | $50.77M | $131.98M |
| Total Current Liabilities | $175.08M | $163.78M | $78.88M | $53.77M | $134.54M |
| Long Term Debt | $- | $178.57M | $189.65M | $189.98M | $194.25M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $212.00K |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $-212.00K |
| Other Non-Current Liabilities | $164.96M | $2.11M | $2.50M | $3.18M | $1.10M |
| Total Non-Current Liabilities | $164.96M | $180.68M | $192.15M | $193.16M | $195.35M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $340.05M | $344.46M | $271.03M | $246.94M | $329.89M |
| Preferred Stock | $- | $- | $- | $0 | $427.07M |
| Common Stock | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K |
| Retained Earnings | $2.22M | $-143.28M | $-272.13M | $-453.60M | $-488.19M |
| Accumulated Other Comprehensive Income Loss | $66.00K | $2.00K | $-151.00K | $-0 | $-427.07M |
| Other Total Stockholders Equity | $656.87M | $610.27M | $675.12M | $640.10M | $1.01B |
| Total Stockholders Equity | $659.15M | $466.99M | $402.84M | $186.51M | $97.18M |
| Total Equity | $659.15M | $466.99M | $402.84M | $186.51M | $97.18M |
| Total Liabilities and Stockholders Equity | $999.20M | $811.45M | $673.87M | $433.44M | $427.07M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $999.20M | $811.45M | $673.87M | $433.44M | $427.07M |
| Total Investments | $123.06M | $113.97M | $101.90M | $750.00K | $750.00K |
| Total Debt | $16.25M | $193.57M | $191.65M | $191.98M | $194.25M |
| Net Debt | $-436.75M | $-118.09M | $-52.14M | $-42.33M | $-34.38M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $453.00M | $387.37M | $317.30M | $332.98M | $311.66M | $324.60M | $317.42M | $287.96M | $243.78M | $261.34M | $236.53M | $224.50M | $234.31M | $189.70M | $159.69M | $141.17M | $228.63M | $221.74M | $76.28M | $71.52M |
| Short Term Investments | $14.19M | $23.11M | $29.61M | $39.37M | $41.80M | $46.07M | $53.57M | $55.92M | $79.33M | $46.42M | $17.64M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $467.19M | $410.48M | $346.91M | $372.35M | $353.46M | $370.67M | $370.98M | $343.88M | $323.12M | $307.76M | $254.17M | $224.50M | $234.31M | $189.70M | $159.69M | $141.17M | $228.63M | $221.74M | $76.28M | $71.52M |
| Net Receivables | $83.03M | $81.50M | $83.16M | $79.72M | $74.14M | $67.26M | $63.81M | $52.58M | $54.74M | $55.06M | $49.82M | $38.13M | $34.84M | $33.21M | $31.20M | $23.61M | $22.18M | $16.33M | $15.24M | $11.31M |
| Inventory | $7.20M | $6.92M | $5.64M | $5.86M | $5.36M | $5.09M | $4.85M | $4.09M | $4.30M | $3.90M | $4.21M | $4.60M | $4.43M | $4.80M | $4.95M | $4.41M | $3.82M | $2.31M | $2.08M | $1.87M |
| Other Current Assets | $21.84M | $23.51M | $22.63M | $21.58M | $18.11M | $19.97M | $15.99M | $17.54M | $18.13M | $15.35M | $14.50M | $13.03M | $10.86M | $12.98M | $8.88M | $8.55M | $8.26M | $9.87M | $4.68M | $5.81M |
| Total Current Assets | $579.25M | $522.40M | $458.34M | $479.50M | $451.07M | $463.00M | $455.64M | $418.09M | $400.29M | $382.08M | $322.70M | $280.26M | $284.44M | $240.69M | $204.71M | $177.74M | $262.89M | $250.24M | $98.29M | $90.50M |
| Property Plant Equipment Net | $1.26M | $750.00K | $3.26M | $3.26M | $371.00K | $428.00K | $572.00K | $470.00K | $573.00K | $680.00K | $695.00K | $748.00K | $820.00K | $937.00K | $944.00K | $842.00K | $938.00K | $1.04M | $1.14M | $1.23M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $113.26M | $119.22M | $125.19M | $131.15M | $137.11M | $143.07M | $149.03M | $154.99M | $160.95M | $166.91M | $172.88M | $178.84M | $143.92M | $148.56M | $153.13M | $157.76M | $162.34M | $66.62M | $68.49M | $70.40M |
| Goodwill and Intangible Assets | $113.26M | $119.22M | $125.19M | $131.15M | $137.11M | $143.07M | $149.03M | $154.99M | $160.95M | $166.91M | $172.88M | $178.84M | $143.92M | $148.56M | $153.13M | $157.76M | $162.34M | $66.62M | $68.49M | $70.40M |
| Long Term Investments | $108.87M | $94.22M | $87.45M | $81.51M | $72.17M | $67.70M | $58.65M | $48.54M | $22.57M | $8.28M | $4.75M | $750.00K | $750.00K | $750.00K | $750.00K | $750.00K | $- | $- | $- | $- |
| Tax Assets | $190.40M | $185.02M | $180.19M | $147.64M | $144.16M | $100.48M | $93.58M | $89.39M | $85.94M | $81.68M | $- | $-750.00K | $-750.00K | $-750.00K | $-750.00K | $-750.00K | $- | $- | $- | $- |
| Other Non-Current Assets | $6.16M | $6.52M | $3.96M | $3.92M | $6.57M | $3.09M | $2.71M | $3.62M | $3.55M | $3.83M | $4.01M | $4.16M | $4.26M | $902.00K | $902.00K | $902.00K | $902.00K | $2.17M | $902.00K | $959.00K |
| Total Non-Current Assets | $419.95M | $405.73M | $400.04M | $367.48M | $360.38M | $314.77M | $304.54M | $297.00M | $273.58M | $261.38M | $182.33M | $183.75M | $149.00M | $150.40M | $154.98M | $159.51M | $164.18M | $69.83M | $70.53M | $72.59M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $999.20M | $928.13M | $858.38M | $846.99M | $811.45M | $777.77M | $760.18M | $715.09M | $673.87M | $643.46M | $505.03M | $464.00M | $433.44M | $391.09M | $359.69M | $337.25M | $427.07M | $320.07M | $168.82M | $163.09M |
| Account Payables | $13.74M | $10.53M | $22.68M | $15.14M | $17.73M | $6.54M | $6.56M | $6.41M | $3.79M | $10.05M | $6.66M | $6.90M | $1.00M | $4.18M | $2.01M | $4.39M | $2.56M | $9.35M | $2.07M | $4.85M |
| Short Term Debt | $16.25M | $15.00M | $15.00M | $15.00M | $15.00M | $15.00M | $11.00M | $6.50M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $123.24M | $83.08M | $71.53M | $- | $- | $- | $- | $- | $49.41M | $41.01M | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $145.09M | $135.75M | $108.90M | $124.11M | $131.05M | $90.87M | $75.48M | $72.45M | $73.10M | $95.31M | $57.10M | $47.62M | $50.77M | $41.44M | $34.59M | $29.05M | $131.98M | $22.44M | $18.99M | $11.60M |
| Total Current Liabilities | $175.08M | $161.28M | $146.58M | $154.25M | $163.78M | $112.41M | $93.05M | $85.36M | $78.88M | $107.36M | $65.76M | $56.53M | $53.77M | $47.62M | $36.59M | $33.44M | $134.54M | $31.79M | $21.06M | $16.45M |
| Long Term Debt | $- | $167.85M | $171.42M | $175.00M | $178.57M | $182.13M | $180.49M | $185.06M | $189.65M | $189.72M | $189.81M | $189.90M | $189.98M | $190.07M | $195.61M | $194.91M | $194.25M | $192.86M | $192.52M | $192.18M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $192.00K | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-192.00K | $- | $- | $- | $- |
| Other Non-Current Liabilities | $164.96M | $2.21M | $1.80M | $2.34M | $2.11M | $1.90M | $1.48M | $1.62M | $2.50M | $2.50M | $2.93M | $3.08M | $3.18M | $1.38M | $939.00K | $1.02M | $1.10M | $876.00K | $4.59M | $4.15M |
| Total Non-Current Liabilities | $164.96M | $170.05M | $173.22M | $177.34M | $180.68M | $184.03M | $181.97M | $186.69M | $192.15M | $192.22M | $192.74M | $192.97M | $193.16M | $191.45M | $196.55M | $195.94M | $195.35M | $193.73M | $197.11M | $196.33M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $340.05M | $331.33M | $319.80M | $331.59M | $344.46M | $296.43M | $275.01M | $272.05M | $271.03M | $299.58M | $258.50M | $249.50M | $246.94M | $239.07M | $233.14M | $229.37M | $329.89M | $225.52M | $218.17M | $212.78M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $0 | $0 | $- | $- | $- | $0 | $320.07M | $437.95M | $422.64M |
| Common Stock | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K |
| Retained Earnings | $2.22M | $-47.26M | $-93.35M | $-104.94M | $-143.28M | $-169.88M | $-208.34M | $-242.65M | $-272.13M | $-320.64M | $-408.58M | $-432.11M | $-453.60M | $-476.31M | $-466.69M | $-480.81M | $-488.19M | $-487.99M | $-483.36M | $-472.33M |
| Accumulated Other Comprehensive Income Loss | $66.00K | $499.00K | $-234.00K | $-171.00K | $2.00K | $-516.00K | $-522.00K | $-31.00K | $-151.00K | $-178.00K | $-29.00K | $-0 | $-0 | $0 | $0 | $- | $-0 | $-320.07M | $-437.95M | $0 |
| Other Total Stockholders Equity | $656.87M | $643.56M | $632.17M | $620.51M | $610.27M | $651.73M | $694.04M | $685.72M | $675.12M | $664.70M | $655.14M | $646.62M | $640.10M | $628.33M | $593.24M | $588.69M | $585.37M | $902.61M | $- | $3.50M |
| Total Stockholders Equity | $659.15M | $596.80M | $538.58M | $515.39M | $466.99M | $481.33M | $485.17M | $443.04M | $402.84M | $343.88M | $246.53M | $214.50M | $186.51M | $152.02M | $126.55M | $107.88M | $97.18M | $94.55M | $-49.35M | $-49.69M |
| Total Equity | $659.15M | $596.80M | $538.58M | $515.39M | $466.99M | $481.33M | $485.17M | $443.04M | $402.84M | $343.88M | $246.53M | $214.50M | $186.51M | $152.02M | $126.55M | $107.88M | $97.18M | $94.55M | $-49.35M | $-49.69M |
| Total Liabilities and Stockholders Equity | $999.20M | $928.13M | $858.38M | $846.99M | $811.45M | $777.77M | $760.18M | $715.09M | $673.87M | $643.46M | $505.03M | $464.00M | $433.44M | $391.09M | $359.69M | $337.25M | $427.07M | $320.07M | $168.82M | $163.09M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $999.20M | $928.13M | $858.38M | $846.99M | $811.45M | $777.77M | $760.18M | $715.09M | $673.87M | $643.46M | $505.03M | $464.00M | $433.44M | $391.09M | $359.69M | $337.25M | $427.07M | $320.07M | $168.82M | $163.09M |
| Total Investments | $123.06M | $117.33M | $117.06M | $120.88M | $113.97M | $113.77M | $112.22M | $104.45M | $101.90M | $54.70M | $22.39M | $750.00K | $750.00K | $750.00K | $750.00K | $750.00K | $- | $- | $- | $- |
| Total Debt | $16.25M | $182.85M | $219.26M | $193.06M | $193.57M | $197.13M | $191.49M | $191.56M | $191.65M | $191.72M | $191.81M | $191.90M | $191.98M | $192.07M | $195.61M | $194.91M | $194.25M | $192.86M | $192.52M | $192.18M |
| Net Debt | $-436.75M | $-204.52M | $-98.03M | $-139.92M | $-118.09M | $-127.47M | $-125.93M | $-96.40M | $-52.14M | $-69.62M | $-44.73M | $-32.60M | $-42.33M | $2.37M | $35.92M | $53.74M | $-34.38M | $-28.88M | $116.24M | $120.66M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $145.49M | $128.85M | $181.47M | $34.60M | $-36.94M |
| Depreciation and Amortization | $24.11M | $24.36M | $23.39M | $18.84M | $10.24M |
| Deferred Income Tax | $-29.30M | $-13.42M | $-85.94M | $26.15M | $25.75M |
| Stock Based Compensation | $42.60M | $31.70M | $26.17M | $15.66M | $4.69M |
| Change in Working Capital | $- | $35.03M | $-4.11M | $631.00K | $-11.63M |
| Accounts Receivables | $-8.89M | $-19.40M | $-19.90M | $-12.67M | $-17.92M |
| Inventory | $-1.83M | $-1.07M | $135.00K | $-609.00K | $-2.73M |
| Accounts Payables | $- | $8.95M | $2.79M | $-1.55M | $-3.80M |
| Other Working Capital | $- | $46.55M | $12.87M | $15.46M | $12.83M |
| Other Non Cash Items | $36.91M | $12.85M | $3.49M | $2.68M | $4.91M |
| Net Cash Provided by Operating Activities | $219.82M | $219.39M | $144.47M | $98.56M | $-2.98M |
| Investments in Property Plant and Equipment | $-1.15M | $-312.00K | $-40.17M | $-100.30M | $-2.00M |
| Acquisitions Net | $-33.07M | $-36.97M | $141.83M | $-100.00M | $-2.00M |
| Purchases of Investments | $-105.29M | $-127.47M | $-110.73M | $- | $- |
| Sales Maturities of Investments | $98.53M | $118.31M | $9.07M | $- | $- |
| Other Investing Activities | $-26.50M | $- | $-141.83M | $100.00M | $2.00M |
| Net Cash Used for Investing Activities | $-67.48M | $-46.44M | $-141.83M | $-100.30M | $-2.00M |
| Debt Repayment | $-15.00M | $-1.25M | $-2.00M | $-500.00K | $79.42M |
| Common Stock Issued | $- | $- | $8.84M | $30.00M | $147.63M |
| Common Stock Repurchased | $- | $-100.00M | $- | $- | $-167.00K |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $4.00M | $-4.30M | $8.84M | $-22.08M | $-17.71M |
| Net Cash Used Provided by Financing Activities | $-11.00M | $-105.55M | $6.84M | $7.42M | $209.16M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $141.34M | $67.40M | $9.47M | $5.68M | $204.17M |
| Cash at End of Period | $453.27M | $311.93M | $244.53M | $235.06M | $229.38M |
| Cash at Beginning of Period | $311.93M | $244.53M | $235.06M | $229.38M | $25.21M |
| Operating Cash Flow | $219.82M | $219.39M | $144.47M | $98.56M | $-2.98M |
| Capital Expenditure | $-1.15M | $-312.00K | $-40.17M | $-100.30M | $-2.00M |
| Free Cash Flow | $218.67M | $219.07M | $104.29M | $-1.74M | $-4.99M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $49.48M | $46.09M | $11.59M | $38.33M | $26.61M | $38.46M | $34.30M | $29.48M | $48.51M | $87.94M | $23.53M | $21.48M | $22.71M | $-9.62M | $14.12M | $7.39M | $-208.00K | $1.91M | $-27.00K | $-38.62M |
| Depreciation and Amortization | $5.97M | $5.97M | $6.05M | $6.12M | $6.12M | $6.11M | $6.06M | $6.06M | $6.07M | $6.06M | $6.05M | $5.20M | $4.76M | $4.67M | $4.73M | $4.68M | $4.38M | $1.97M | $2.00M | $1.88M |
| Deferred Income Tax | $-6.71M | $-4.83M | $-14.28M | $-3.48M | $1.12M | $-6.91M | $-4.19M | $-3.44M | $-4.26M | $-81.68M | $- | $- | $- | $26.15M | $- | $- | $- | $1.52M | $438.00K | $23.79M |
| Stock Based Compensation | $10.07M | $11.05M | $11.09M | $10.39M | $8.86M | $7.99M | $7.65M | $7.20M | $7.26M | $7.01M | $7.28M | $4.63M | $4.20M | $4.25M | $3.91M | $3.30M | $2.82M | $1.07M | $429.00K | $368.00K |
| Change in Working Capital | $15.82M | $11.70M | $-14.51M | $-20.33M | $31.64M | $6.73M | $-7.08M | $3.74M | $-32.01M | $35.45M | $-4.02M | $-3.52M | $5.26M | $4.12M | $-5.30M | $-3.45M | $-444.00K | $1.76M | $1.62M | $-14.56M |
| Accounts Receivables | $-1.53M | $1.66M | $-3.44M | $-5.58M | $-6.88M | $-3.45M | $-11.24M | $2.17M | $325.00K | $-5.24M | $-11.69M | $-3.29M | $-1.64M | $-2.01M | $-7.58M | $-1.44M | $-5.85M | $-1.09M | $-3.93M | $-7.05M |
| Inventory | $-283.00K | $-1.27M | $214.00K | $-494.00K | $-276.00K | $-233.00K | $-764.00K | $207.00K | $-397.00K | $308.00K | $389.00K | $-165.00K | $373.00K | $146.00K | $-546.00K | $-582.00K | $-1.51M | $-228.00K | $-212.00K | $-783.00K |
| Accounts Payables | $3.21M | $-12.15M | $6.14M | $-2.59M | $6.20M | $-24.00K | $149.00K | $2.63M | $-6.26M | $3.39M | $-243.00K | $5.90M | $-3.18M | $2.17M | $-2.38M | $1.83M | $-6.79M | $7.27M | $-2.78M | $-1.51M |
| Other Working Capital | $14.42M | $23.47M | $-17.43M | $-11.67M | $32.60M | $10.44M | $4.77M | $-1.26M | $-25.67M | $36.99M | $7.52M | $-5.97M | $9.70M | $3.81M | $5.21M | $-3.26M | $13.71M | $-4.19M | $8.54M | $-5.22M |
| Other Non Cash Items | $943.00K | $518.00K | $62.95M | $31.39M | $2.30M | $10.72M | $323.00K | $-493.00K | $1.11M | $425.00K | $889.00K | $1.06M | $603.00K | $850.00K | $617.00K | $614.00K | $3.49M | $597.00K | $372.00K | $447.00K |
| Net Cash Provided by Operating Activities | $75.56M | $70.50M | $42.62M | $31.14M | $76.67M | $63.10M | $37.06M | $42.56M | $26.68M | $55.20M | $33.73M | $28.85M | $37.53M | $30.42M | $18.07M | $12.53M | $10.05M | $8.84M | $4.83M | $-26.70M |
| Investments in Property Plant and Equipment | $-513.00K | $-3.00K | $-632.00K | $-5.00K | $-107.00K | $- | $-205.00K | $- | $40.17M | $-86.00K | $-41.00K | $-40.05M | $100.30M | $-93.00K | $-201.00K | $-100.00M | $-2.00M | $- | $-2.00K | $- |
| Acquisitions Net | $- | $- | $-33.07M | $- | $-44.53M | $- | $7.57M | $- | $- | $-872.00K | $- | $- | $-100.00M | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-35.69M | $-23.29M | $-21.21M | $-25.11M | $-21.61M | $-33.01M | $-25.07M | $-47.78M | $-55.09M | $-33.23M | $-22.41M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $30.01M | $24.04M | $25.56M | $18.93M | $22.62M | $32.20M | $17.50M | $45.99M | $8.20M | $872.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $-1.00M | $- | $-25.50M | $-6.18M | $7.57M | $-813.00K | $-7.57M | $-1.79M | $-40.17M | $872.00K | $-22.41M | $-40.00M | $100.00M | $- | $- | $-100.00M | $-2.00M | $- | $- | $- |
| Net Cash Used for Investing Activities | $-7.19M | $745.00K | $-54.86M | $-6.19M | $-36.06M | $-813.00K | $-7.77M | $-1.79M | $-46.90M | $-32.45M | $-22.45M | $-40.05M | $100.30M | $-93.00K | $-201.00K | $-100.00M | $-2.00M | $- | $-2.00K | $- |
| Debt Repayment | $-3.75M | $-3.75M | $-3.75M | $-3.75M | $-3.75M | $200.00M | $-500.00K | $-500.00K | $-500.00K | $-500.00K | $-500.00K | $-500.00K | $-500.00K | $-22.00M | $- | $- | $- | $- | $- | $79.42M |
| Common Stock Issued | $- | $-689.00K | $573.00K | $116.00K | $- | $244.00K | $675.00K | $3.91M | $-408.00K | $2.55M | $1.25M | $1.88M | $7.58M | $30.83M | $648.00K | $12.00K | $147.63M | $- | $- | $- |
| Common Stock Repurchased | $- | $269.00K | $-269.00K | $- | $-50.00M | $-50.00M | $-514.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-167.00K | $- | $-167.00K | $- |
| Dividends Paid | $- | $- | $- | $- | $-55.26M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-44.91M | $- | $- | $- |
| Other Financing Activities | $1.01M | $2.58M | $304.00K | $116.00K | $55.49M | $-255.10M | $161.00K | $3.91M | $3.16M | $2.55M | $1.25M | $1.88M | $7.57M | $21.69M | $648.00K | $12.00K | $-1.16M | $-11.01M | $- | $-5.65M |
| Net Cash Used Provided by Financing Activities | $-2.74M | $-1.18M | $-3.45M | $-3.63M | $-53.52M | $-55.10M | $-339.00K | $3.41M | $2.66M | $2.05M | $750.00K | $1.38M | $7.07M | $-313.00K | $648.00K | $12.00K | $-1.16M | $136.62M | $-67.00K | $73.76M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-100.30M | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $65.63M | $70.34M | $-15.69M | $21.32M | $-12.92M | $7.19M | $28.95M | $44.18M | $-17.56M | $24.81M | $12.03M | $-9.81M | $44.60M | $30.02M | $18.52M | $-87.46M | $6.89M | $145.46M | $4.76M | $47.06M |
| Cash at End of Period | $453.27M | $387.64M | $317.30M | $332.98M | $311.93M | $324.85M | $317.67M | $288.71M | $244.53M | $262.09M | $237.28M | $225.25M | $235.06M | $190.45M | $160.44M | $141.92M | $229.38M | $222.49M | $77.03M | $72.27M |
| Cash at Beginning of Period | $387.64M | $317.30M | $332.98M | $311.66M | $324.85M | $317.67M | $288.71M | $244.53M | $262.09M | $237.28M | $225.25M | $235.06M | $190.45M | $160.44M | $141.92M | $229.38M | $222.49M | $77.03M | $72.27M | $25.21M |
| Operating Cash Flow | $75.56M | $70.50M | $42.62M | $31.14M | $76.67M | $63.10M | $37.06M | $42.56M | $26.68M | $55.20M | $33.73M | $28.85M | $37.53M | $30.42M | $18.07M | $12.53M | $10.05M | $8.84M | $4.83M | $-26.70M |
| Capital Expenditure | $-513.00K | $-3.00K | $-632.00K | $-5.00K | $-107.00K | $- | $-205.00K | $- | $40.17M | $-86.00K | $-41.00K | $-40.05M | $100.30M | $-93.00K | $-201.00K | $-100.00M | $-2.00M | $- | $-2.00K | $- |
| Free Cash Flow | $75.05M | $70.50M | $41.98M | $31.14M | $76.56M | $63.10M | $36.86M | $42.56M | $66.85M | $55.12M | $33.69M | $-11.19M | $137.83M | $30.33M | $17.87M | $-87.47M | $8.05M | $8.84M | $4.83M | $-26.70M |
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
$29.44
Stock Price
$1.69B
Market Cap
268
Employees
Plymouth Meeting, PA
Location
Revenue (FY 2024)
$714.73M
22.8% YoY
Net Income (FY 2024)
$145.49M
12.9% YoY
EPS (FY 2024)
$2.51
17.8% YoY
Free Cash Flow (FY 2024)
$218.67M
-0.2% YoY
Profitability
Gross Margin
78.1%
Net Margin
20.4%
ROE
22.1%
ROA
14.6%
Valuation
P/E Ratio
13.45
P/S Ratio
2.74
EV/EBITDA
6.51
Market Cap
$1.69B
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$219.82M
0.2% YoY
Free Cash Flow
$218.67M
-0.2% YoY
Balance Sheet Summary
Total Assets
$999.20M
23.1% YoY
Total Debt
$16.25M
91.6% YoY
Shareholder Equity
$659.15M
47.6% YoY
Dividend Overview
No Dividend Data
Harmony Biosciences Holdings, Inc. doesn't currently pay dividends.
Harmony Biosciences Holdings Dividends
Explore Harmony Biosciences Holdings's dividend history, including dividend yield, payout ratio, and historical payments.
Harmony Biosciences Holdings News
Read the latest news about Harmony Biosciences Holdings, including recent articles, headlines, and updates.
Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 6, 2025, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-267-6316 (domestic) or 203-518-9783 (international), and reference passcode HRMYQ125. It is recommended that you dia.
Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of updated data from its Open-Label Extension (OLE) study (ZYN2-CL-017) evaluating the safety and effectiveness of ZYN002 in children, adolescents, and adults with Fragile X syndrome (FXS). The data showed clinically meaningful improvements in irritability-related symptoms prevalent in individuals with FXS. There are currently no U.S. Food & Drug Administration (FDA) ap.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Reach Out
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Shareholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / April 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Investors to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Ron Philip to the Company's Board of Directors. Ron Philip is the President and Chief Executive Officer of Orbital Therapeutics. Ron has 30 years of experience building companies, leading organizational growth, and guiding teams through the development, regulatory approval, and commercialization of novel therapies. Prior to Orbital, he was Chief Executive Officer of Spark.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Investors to Connect
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Bronstein, Gewirtz & Grossman, LLC Encourages Harmony Biosciences Holdings, Inc. (HRMY) Stockholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Stockholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcoming 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 3:00 p.m. ET. A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is a pharmaceutical com.
Bronstein, Gewirtz & Grossman, LLC Encourages Harmony Biosciences Holdings, Inc. (HRMY) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Investors to Reach Out
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Harmony Biosciences: A Compelling Risk-Reward Opportunity
Harmony Biosciences offers a promising investment with one commercial drug, WAKIX, and a robust pipeline, despite some setbacks and risks. The company's financial health is strong, with significant cash reserves and manageable debt, supporting future R&D and commercialization efforts. Fair value estimates suggest a 70% upside, with a base case valuation of $59.94, and even in a pessimistic scenario, the stock appears fairly valued.
Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the appointment of Adam Zaeske as Executive Vice President and Chief Commercial Officer (CCO), effective March 31, 2025. The company's current CCO, Jeffrey Dierks, is voluntarily stepping down for personal reasons. Zaeske brings 25 years of global leadership across the pharmaceutical industry, building teams and transforming organizations in both the U.S. and Europe. He has broad functiona.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for HRMY.